Genevoyager has developed a series of AAV products rAAV-1.2×HDV carrying 1.2 copies of the full-length HDV genome by taking advantage of the stable expression of AAV8 in host cells and strong hepatophilicity and combining a series of existing and self-developed (Patent No. CN111218446A) liver-specific promoters. This product can be used in combination with the AAV-HBV series to stably establish HBV/HDV co-infection and help the research of HDV replication mechanisms and the R&D of anti-HDV drugs.

Note:

1. The model should be combined with AAV-HBV virus to establish a model of HDV infection.

2. We can customize HDV genomes activated by different liver-specific promoters and their point mutants according to different requirements of customers to facilitate scientific research and antiviral drug development.